A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models

Abstract

Validation and comparison of prognostic models indicated that our model was as effective as the previous models to stratify the patients with AGC.

Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution

“…Overall, 3494 patients (89.9 %) died, with a median OS of 10.6 months (95 % CI 10.2-11.0). The median followup time for living patients was 25.2 months [interquartile According to our previous prognostic model using eight prognostic factors (mentioned previously) [14], the patients were grouped into three groups. In the good risk group, the OS showed statistically significant improvement over the study period: 12.3 months (95 % CI 11.0-13.6) in period 1, 13.0 months (95 % CI 11.8-14.1) in period 2 and 15.8 months (95 % CI 14.9-16.7 months) in period 3 (p for trend = 0.002, Fig.…”

“…Patients' medical records, stored in a prospectively collected registry, were reviewed for information regarding demographic data, tumor characteristics, treatment types, treatment responses and survival. In addition, patients were grouped by our prognostic model for MRGC [14]. This model used a scoring system consisting of eight prognostic factors [Eastern Cooperative Oncology Group (ECOG) performance score (PS) C2 or bone metastasis (2 points each); no gastrectomy, peritoneal metastasis, lung metastasis, alkaline phosphatase [120 IU/ l, albumin \3.3 g/dl or total bilirubin [1.2 mg/dl (1 point each)], with patients divided into good (0-1 points), moderate (2-3) and poor (C4) risk groups.…”

Prediction of Time to Recurrence and Influencing Factors for Gastric Cancer in Iran

“…It is essential to distinguish the nature of recurrent gastric cancer by the occurrence of symptoms and evaluation the risk factors for planning further treatment (Kim et al, 2010). Validation and comparison of prognostic factors will indicate the effective models to predict the patterns of recurrence (Koo et al, 2011). Although several studies have been published on prognostic risk factors generally used in clinical practice for gastric cancer, the patterns of recurrence are still under debate in different societies.…”

Determination of Prognostic Factors in Japanese Patients With Advanced Gastric Cancer Using the Data From a Randomized Controlled Trial, Japan Clinical Oncology Group 9912

“…To select the most optimal of our five candidate models, three of the four factors (PS $1, number of metastatic sites $2, and no prior gastrectomy), excluding elevated ALP and LDH, were included in all models, and we selected elevated ALP from the point of consistency in previous reports [14,15,17]. Both LDH and ALP commonly represent liver function, bone metastasis, and other abnormal conditions; however, there were no previous reports of prognostic models, including LDH.…”

“…Moreover, a few reports have described prognostic factors for GC from Korean patients [15][16][17]. Lee et al [15] reported ECOG PS $2, no prior gastrectomy, peritoneal metastasis, bone metastasis, elevated ALP, and decreased albumin as independent prognostic factors; Kim et al [16] reported ECOG PS $2, peritoneal metastasis, bone metastasis, metastatic sites $2, and elevated total bilirubin as prognostic factors; and Koo et al [17] reported ECOG PS $2, no prior gastrectomy, peritoneal metastasis, bone metastasis, lung metastasis, elevated ALP, decreased albumin, and elevated total bilirubin as prognostic factors. Only PS was a common prognostic factor in all four studies, and peritoneal and bone metastasis were shared among three studies.…”